This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n8http://localhost/temp/predkladatel/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n20http://linked.opendata.cz/resource/domain/vavai/subjekt/
n9http://linked.opendata.cz/ontology/domain/vavai/
n14http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11110%2F11%3A9964%21RIV12-MSM-11110___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11110%2F11%3A9964%21RIV12-MSM-11110___
rdf:type
n9:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1136/ard.2010.141051
dcterms:description
Recent studies show an important role of type I interferon (IFN) in the pathogenesis Idiopathic inflammatory myopathies. In order to investigate the relationship of soluble IFNalpha serum levels with clinical and laboratory characteristics we analysed serum samples of 43 patients with dermatomyositis (DM) or polymyositis (PM). Patients were selected with the preference for those who were anti-Jo-1 positive, and had muscle MRI performed. Significantly lower levels of IFNalpha were found in patients with myositis in comparison with control groups. There were no significant differences in IFNalpha levels between patients with PM and those with DM. IFNalpha levels were significantly higher in patients who were anti-Jo-1 positive (n=26; median 117.8 pg/ml, range 70–378) in comparison to patients who were anti-Jo-1 negative (n=17; median 93.4 pg/ml, range 0–199) (p=0.05), which is in accordance with described IFNalpha-inducing capacity of anti-Jo-1 positive serum samples. A statistically significant negative correlation was found between IFNalpha and the intensity of MRI signal. None of the clinical or laboratory parameters of activity, showed any correlation with IFNalpha levels, with the exception of the tendency to higher IFNalpha levels (p=0.064) in the presence of interstitial lung disease detected by high- resolution CT (n=22) or chest x-ray (n=4). Serum levels of IFNalpha do not seem to be an indicator of clinical activity, rather the opposite; the lower the serum level the more severe the muscle oedema, as demonstrated by the intensity parameter on MRI. Hypothetically, IFNalpha produced locally could be also locally consumed and not released into the circulation. Alternatively, other type I IFNs and not the IFNalpha may be responsible for the type I IFN signature that is characteristic for many patients with DM and PM. Recent studies show an important role of type I interferon (IFN) in the pathogenesis Idiopathic inflammatory myopathies. In order to investigate the relationship of soluble IFNalpha serum levels with clinical and laboratory characteristics we analysed serum samples of 43 patients with dermatomyositis (DM) or polymyositis (PM). Patients were selected with the preference for those who were anti-Jo-1 positive, and had muscle MRI performed. Significantly lower levels of IFNalpha were found in patients with myositis in comparison with control groups. There were no significant differences in IFNalpha levels between patients with PM and those with DM. IFNalpha levels were significantly higher in patients who were anti-Jo-1 positive (n=26; median 117.8 pg/ml, range 70–378) in comparison to patients who were anti-Jo-1 negative (n=17; median 93.4 pg/ml, range 0–199) (p=0.05), which is in accordance with described IFNalpha-inducing capacity of anti-Jo-1 positive serum samples. A statistically significant negative correlation was found between IFNalpha and the intensity of MRI signal. None of the clinical or laboratory parameters of activity, showed any correlation with IFNalpha levels, with the exception of the tendency to higher IFNalpha levels (p=0.064) in the presence of interstitial lung disease detected by high- resolution CT (n=22) or chest x-ray (n=4). Serum levels of IFNalpha do not seem to be an indicator of clinical activity, rather the opposite; the lower the serum level the more severe the muscle oedema, as demonstrated by the intensity parameter on MRI. Hypothetically, IFNalpha produced locally could be also locally consumed and not released into the circulation. Alternatively, other type I IFNs and not the IFNalpha may be responsible for the type I IFN signature that is characteristic for many patients with DM and PM.
dcterms:title
Serum levels of interferon alpha do not correlate with disease activity in patients with dermatomyositis/polymyositis Serum levels of interferon alpha do not correlate with disease activity in patients with dermatomyositis/polymyositis
skos:prefLabel
Serum levels of interferon alpha do not correlate with disease activity in patients with dermatomyositis/polymyositis Serum levels of interferon alpha do not correlate with disease activity in patients with dermatomyositis/polymyositis
skos:notation
RIV/00216208:11110/11:9964!RIV12-MSM-11110___
n9:predkladatel
n20:orjk%3A11110
n3:aktivita
n11:Z n11:S
n3:aktivity
S, Z(MSM0021620806)
n3:cisloPeriodika
5
n3:dodaniDat
n12:2012
n3:domaciTvurceVysledku
n4:3978214 n4:8827559 n4:7250169 n4:1222511 n4:3455750 n4:3039145
n3:druhVysledku
n17:J
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n18:predkladatel
n3:idSjednocenehoVysledku
228973
n3:idVysledku
RIV/00216208:11110/11:9964
n3:jazykVysledku
n5:eng
n3:klicovaSlova
dermatomyositis; polymyositis; Interferon alpha; muscle MRI; anti-Jo-1
n3:klicoveSlovo
n6:polymyositis n6:dermatomyositis n6:anti-Jo-1 n6:Interferon%20alpha n6:muscle%20MRI
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[EA41498E93B5]
n3:nazevZdroje
Annals of the Rheumatic Diseases
n3:obor
n19:FE
n3:pocetDomacichTvurcuVysledku
6
n3:pocetTvurcuVysledku
7
n3:rokUplatneniVysledku
n12:2011
n3:svazekPeriodika
70
n3:tvurceVysledku
Vencovský, Jiří Mann, Heřman Klein, M. Kryštufková, Olga Beran, Ondřej Król, Petra Polanská, Markéta
n3:wos
000289070500032
n3:zamer
n14:MSM0021620806
s:issn
0003-4967
s:numberOfPages
2
n8:organizacniJednotka
11110